Lab-grown islets for transplant

Seraxis Islets mimic native islets from a human pancreas

Seraxis has effectively produced islets which are identical to native pancreas islets.

Seraxis Islets secrete insulin and glucagon like a native islet

Biphasic response to glucose demonstrates Seraxis islets have mature islet molecular machinery

Seraxis islets respond to Tolbutamide and Diazoxide the same way a native pancreas does. These are two common drugs that are administered to diabetics to regulate insulin secretion.

Reliable production of stem cell-derived islets

• Large-scale manufacturing yields reproducible, consistent batches of islets at 95-100% purity
• No cell sorting or selection necessary
• Clusters contain 60-90% insulin-secreting beta cells
• No use of viruses, no integrating plasmid
• Never exposed to serum or any animal products
• Favorable risk:benefit ratio due to lack of tumorigenicity and high potency

Seraxis islets are derived from an immortal “iPS-variant” line that was created by Seraxis from a human islet. This line is proprietary, patented, and stored as a cGMP compliant master cell bank.

Unique source of human islets

Unlike Seraxis, no group has ever published

• reliable production of stem cell-derived islets at more than 30% purity without physical non-scalable selection of individual cells
• production of pure islets (with insulin, glucagon, and the other pancreatic hormones) from stem cells that is not contaminated by non-pancreatic cells
• consistent production of pure, high-potency islets from stem cells (embryonic stem or iPS cells) in scalable, large-format closed culture systems
• achieving these goals without the use of serum, animal products, and other non-defined reagents